These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37395023)

  • 1. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
    Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
    Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
    Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
    Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
    Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
    Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
    Zhang K; Xie X; Zou LH; Guo SQ
    Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Sun J; Yan C; Xu D; Zhang Z; Li K; Li X; Zhou M; Hao D
    Br J Cancer; 2022 Jun; 126(11):1570-1580. PubMed ID: 35017656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Role of Cuproptosis in Head and Neck Squamous Cell Carcinoma Patients: A Comprehensive Analysis.
    Ding Q; Chen X; Hong W; Wang L; Liu W; Cai S; Chen X; Lu J; Qiu S
    Dis Markers; 2022; 2022():9996946. PubMed ID: 36092958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis.
    Su H; Jin Y; Tao C; Yang H; Yang E; Zhang WG; Feng F
    J Gynecol Oncol; 2023 Jul; 34(4):e48. PubMed ID: 36998223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
    Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
    Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes.
    Meng C; Sun Y; Liu G
    Front Oncol; 2023; 13():1144430. PubMed ID: 37256178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.